Quantum Genomics extends its collaboration agreement with its partner in animal health
Companies to continue joint development of therapies to treat heart failure in dogs
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has extended its collaboration agreement with its partner, a world leader in animal health.
Under this agreement, the two companies will continue working together to initiate additional clinical trials of the drug candidate developed by Quantum Genomics for the treatment of heart failure in dogs. The specific financial terms of the contact remain undisclosed.
Lionel Segard, Quantum Genomics' President and Chief Executive Officer, commented:
“The goal of this partnership is to overcome heart failure challenges in dogs. We are pleased to extend our collaboration with a major player in the industry and continue the evaluation of veterinary applications for our unique therapeutic candidates. We believe such collaborative veterinary clinical development efforts will further strengthen our position in the field of heart failure, at a time when we are launching our Phase IIa trial in humans.”
CONTACTS
Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 [email protected] ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 [email protected] The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592 |
ABOUT QUANTUM GENOMICS Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure. The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes. Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com. |
Regulated information
Releases under ongoing disclosure requirements:
- other releases
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-44752-QUANTUM_CP_Collaboration-sante-animale_28062016_VDEF_EN.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews